Botanix Pharmaceuticals Limited (Botanix or the Company) announced the expansion of its management team with three new key hires in the US to drive its antimicrobial and dermatology programs. Dr. Clarence Young joins Botanix as Chief Medical Officer, Anthony Robinson joins as Vice President of Development and Lynda Berne joins as Head of Commercial. Dr. Young was recently Chief Medical Officer at Velicept Therapeutics and Senior Vice-President and Chief Medical Officer at Iroko Pharmaceuticals, where he provided clinical and medical leadership for three NDA filings and approvals. He also has held executive leadership positions for Novartis and one of its acquisitions, Protez Pharmaceuticals, where he served as Vice President, Drug Development and Chief Medical Officer. Dr. Young began his pharmaceutical career at GlaxoSmithKline, where he was Vice President and Global Head, Anti-Infectives Clinical Development. Dr. Young is a Fellow of the Infectious Diseases Society of America and served on the White House Working Group on Antimicrobial Resistance. He is a graduate of Williams College and Harvard Medical School and the author of numerous peer reviewed articles, reviews and scientific presentations. Anthony Robinson was recently Vice President, Head of Clinical Operations, Program Management and Regulatory Affairs at Advicenne and previously held similar positions at Aquestive Therapeutics and Intrommune Therapeutics, and developed extensive expertise in drug development, clinical operations and regulatory affairs at Shire Pharmaceuticals (acquired by Takeda) and global contract research organisation, Covance. Anthony holds multiple qualifications including an MBA from Penn State University, a Master of Science from Drexel University and a Bachelor of Science from Cornell University.